Novartis files CAR-T in lymphoma, sets up rivalry with Gilead – pharmaphorum
pharmaphorum |
Novartis files CAR–T in lymphoma, sets up rivalry with Gilead
pharmaphorum The new US filing announced today means Novartis is pursuing approval in relapsed/refractory diffuse large B-cell (r/r DLBCL) lymphoma patients ineligible for autologous stem cell transplant. Kymriah was the first CAR–T drug to gain US approval in … Novartis asks FDA to expand Kymriah's use against blood cancer Novartis submits application to FDA for KymriahTM (tisagenlecleucel … Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL |
